PTO/SB/08a (05-03) Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete If Known Substitute for form 1449A/PTO Application Number 10/680,959 INFORMATION DISCLOSURE Filing Date October 7, 2003 STATEMENT BY APPLICANT First Named Inventor KNOX, SUSAN JANE Art Unit 1651 (use as many sheets as necessary) **Examiner Name** Sheet of **Attorney Docket Number STAN-274**

U.S. PATENT DOCUMENTS									
		Document Number			Pages, Columns, Lines, Where				
Examiner Initiats'	Cite No.1	Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear				
(L)X		US- 6,265,417	July 24, 2001	Carroll, et al.					
		US-							

FOREIGN PATENT DOCUMENTS									
Examiner Initials'	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶			
OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS									
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),							
aly	GILBERT et al., Association of BCL-2 With Membrane Hyperpolarization and Radioresistance, J. Cell. Physiol., (1996), 168:114-122								
		HAEUSLER, K ⁺ - Channel Openers: New Antihypertensive Drugs?, Clin Physiol Biochem, (1990), 8 (Suppl 2):46-56							
		LAWSON, Potassium channel openers as potential therapeutic weapons in ion channel disease, Kidney Int, (2000), 57:838-45							
		MCPHERSON, Current Tren Gen Pharmacol, (1993), 24		udy of Potassium C	hannel Openers,				
		MIRKOVIC et al., Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols, Oncogene, (1997), 15:1461-1470							

7			
Examiner	florame Vossom	Date	7/13/04
Signature	Leave to the contract of	Considered	

*EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.